A novel series of pyrazolones was recently identifi ed as potent inhibitors of c-Met. Increased selectivity over VEGFR-2 was achieved with the incorporation of a 2-hydroxypropyl group in the N1 position of the pyrazolone ring. Analysis of both in vitro and in vivo studies revealed oxidation of the hydroxyl group to form the corresponding ketone; an active metabolite lacking selectivity over VEGFR-2. Subsequent modifi cation of the 2-hydroxypropyl group led to the discovery of 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458), a molecule that exhibits a favorable pharmacokinetic profi le in mouse, rat, dog, and monkey. Moreover, AMG 458 signifi cantly inhibited tumor growth when dosed orally in the TPR-Met and U-87 MG xenograft models with no adverse eff ect on body weight. As a result, AMG 458 was progressed as a potential clinical candidate for the treatment of human cancers.
Background
c-Met is a receptor tyrosine kinase that is activated by its ligand, hepatocyte growth factor/ scatter factor (HGF/SF) (1, 2) . Upon activation, the intracellular C-terminal docking domain recruits and subsequently activates a wide range of downstream signaling molecules that contribute to the survival, proliferation, migration, and invasion of cells (3) (4) (5) . Transient activation of c-Met by HGF through a paracrine mechanism is important during embryogenesis and tissue repair. However, over-expression of HGF and/or c-Met or activating mutations of c-Met have been linked to human cancers. Among various approaches that target the c-Met/HGF signaling pathway (6) (7) (8) (9) , inhibition of the c-Met kinase activity with small molecules has the potential to block both the ligand-dependent and ligand-independent activation of c-Met. Th is approach has recently been supported by the reported anti-tumor activity of a small molecule inhibitor of c-Met in a variety of c-Met driven human tumor xenograft models (10) .
Clinical and Translational Leads
We were intrigued by the structural features of acylthiourea A (Fig. 1) when disclosed in the patent literature (11) as a c-Met kinase inhibitor. Structural similarities with kinase inhibitors such as imatinib were observed indicating the potential for binding to the inactive form of the kinase (12) . In an eff ort to reduce potential liabilities associated with the acylthiourea functionality and conformationally restrain the molecule while maintaining key hydrogen bonds with the protein; the acylthiourea was replaced with an aminoacylpyrazolone ring.
Th e initial N1-methyl pyrazolone was identifi ed as a potent c-Met inhibitor, but demonstrated minimal selectivity against VEGFR-2 ( Table 1, compound 1) . Th e replacement of the N1 methyl group with a propyl group (compound 2) signifi cantly enhanced selectivity; however, further branching to an isopropyl moiety (compound 3) resulted in reduced activity at the cellular level. Interestingly, the introduction of a secondary hydroxyl group (compounds 4 and 5) maintained both enzyme and cellular potency relative to compound 1, independent of stereochemistry.
Having identifi ed potent and selective inhibitors of c-Met, we examined the in vivo pharmacokinetic profi les of compounds 4 and 5. When dosed iv in rats, enantiomers 4 and 5 exhibited low clearance (CL < 200 mL/h/kg; t 1/2 1.9-2.6 h) and good oral bioavailability (F > 50%). To assess the pharmacological activity of pyrazolone 4, inhibition of HGFmediated c-Met phosphorylation in mouse liver was measured after oral administration. At 30 mg/kg, compound 4 inhibited 98% of c-Met phosphorylation in mouse liver at 6 hours post-dose. Detailed analysis of plasma samples revealed the presence of signifi cant amounts of ketone 6. When dosed orally in mice, compound 4 was quickly converted to the corresponding ketone 6 resulting in a comparable overall exposure for both the alcohol and the ketone. Th ese fi ndings raised concerns that as a potent c-Met inhibitor (c-Met IC 50 2 nM; IC 50 (PC3) 48 nM) with no selectivity over VEGFR-2 (VEGFR-2 IC 50 4 nM; IC 50 (HUVEC) 86 nM), ketone 6 would likely contribute signifi cantly to pharmacological activity.
To eliminate the formation of ketone 6 and thereby provide a more metabolically stable compound, the corresponding tertiary alcohol was prepared. Tertiary alcohol 7 maintained enzyme and cell potency and had slightly better selectivity against VEGFR-2 relative to secondary alcohols 4 and 5. In addition, compound 7 was not signifi cantly converted to a major circulating active metabolite.
In an attempt to improve the overall potency and properties of compound 7, the SAR of this series was further expanded and led to the orally bioavailable and selective c-Met inhibitor AMG 458 (8) . Compound 8 potently inhibited c-Met at both the enzymatic and the cellular levels (c-Met IC 50 2 nM; IC 50 (PC3) = 60 nM; Table 1 ) with no loss of selectivity over VEGFR-2. In addition, compound 8 demonstrated 100-fold selectivity when tested against a panel of 55 tyrosine and serine/threonine kinases. However, compound 8 signifi cantly inhibited Ron, a tyrosine kinase closely related to c-Met, as well as fi ve of the c-Met activating mutations found in human cancers (13, 14) . Due to the excellent in vitro potency and selectivity of compound 8, we assessed the in vitro metabolic stability across species. Compound 8 displayed good metabolic stability in mouse, rat, dog, monkey and human liver microsomes with low intrinsic clearance (<5 and 62, 8, 8, 18 µL/min/mg, respectively). In vivo, inhibitor 8 exhibited low clearance in mouse, dog, and monkey, and low to moderate clearance in rat (Table 2 ). Although compound 8 was rapidly eliminated in mouse and rat with a terminal half life less than 2 hours, a more sustained exposure was achieved in dog and monkey with half lives ranging from 3 to 6 hours, respectively. When administered orally, compound 8 achieved remarkably high bioavailability in all species.
Given the good pharmacokinetic profi le of compound 8, the inhibition of c-Met phosphorylation in vivo was evaluated in a mouse liver pharmacodynamic assay. Compound 8 inhibited HGF-mediated c-Met phosphorylation in a dose-dependent manner with an approximate ED 90 of 30 mg/kg and an associated exposure of approximately 15 µM at 6 hours ( Fig. 2A) . Good correlation was observed between the inhibition of c-Met phosphorylation in liver and plasma concentration.
Th e anti-tumor eff ect of compound 8 as a single agent was then examined in two xenograft models. Inhibitor 8 was fi rst evaluated in a tumor model derived from NIH-3T3 cells transfected with TPR-Met, a constitutively active ligand-independent form of c-Met (15). In the NIH-3T3/TPR-Met model, compound 8 exhibited dose-dependent tumor growth inhibition when administered orally with an ED 50 of ~12 mg/kg (95% CI = 9-16) with an associated AUC (0-24) of 96 µM*h and an ED 90 of ~34 mg/kg (95% CI = 12-94) with an associated AUC (0-24) of 241 µM*h (Fig. 2B) . Compound 8 was further evaluated in the U-87 MG glioblastoma xenograft tumor model in which c-Met activation is induced via binding of its ligand, HGF (autocrine loop) (16, 17) . In this ligand-dependent model, compound 8 inhibited tumor growth when dosed orally with an ED 50 of ~16 mg/kg (95% CI = 9-27) with an associated AUC (0-24) of 130 µM*h and an ED 90 of ~59 mg/kg (95% CI = 22-160) with an associated AUC (0-24) of 482 µM*h (Fig. 2C) . In both xenograft models, tumor growth inhibition was achieved without body weight loss. Th ese encouraging results combined with favorable pharmacokinetic profi les across species warranted advancement of AMG 458 (Table 1 ; compound 8) as a potential clinical candidate. 
